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Abstract
Pregnancy is infrequently complicated by the diagnosis of a concurrent breast cancer. This presents
a particularly complicated clinical problem. The treatment of breast cancer in young women
involves a number of difficult decisions regarding therapy. These decisions become even more
complex when the concerns of the safety of an unborn child are added to the equation. For breast
cancers diagnosed late in the third trimester, it is relatively straight forward to delay therapy until
after delivery. For women diagnosed earlier in pregnancy, there are legitimate concerns that delays
in therapy may adversely affect outcomes. While there are no randomized trials addressing the
optimal treatment of women in this situation, there are case reports, case series, and cohort
experiences that provide some insight. There are recommendations available from an international
working group and from the National Comprehensive Cancer Network that address the treatment
of women in this situation. There is general consensus that both surgery and chemotherapy are
relatively safe after the first trimester of pregnancy. It is generally agreed that therapeutic radiation,
if necessary, should be delayed until completion of pregnancy.
"I'm pregnant" is a phrase most women share with their
partners and family with great joy, anticipation, and exu-
berance. "I have breast cancer" is a phrase all women
dread. A small number of women experience both sets of
emotions in quick succession after being diagnosed with
breast cancer in early pregnancy. It is currently estimated
that 1 in 3000 pregnancies is complicated by breast cancer
[1] and this number is expected to rise with the tendency
of women to delay child bearing in developed countries
[2,3].
In an article published in BMC Cancer, Dr. Epstein
addresses many of the uncertainties that confront a
patient and care team faced with this situation [4]. Here,
we attempt to provide some guidance regarding currently
accepted approaches to this complex situation.
The diagnosis of breast cancer during pregnancy presents
a unique clinical challenge. The management of breast
cancer involves a number of important decisions of high
complexity, often requiring the collaboration of patient,
family, and interdisciplinary care team. Add an early preg-
nancy into the equation and the complexity increases dra-
matically. This is in no small part due to the probabilistic
nature of many of the decisions made in the treatment of
breast cancer. The data we use to make decisions in the
treatment of breast cancer is incomplete and evolving. In
the setting of pregnancy, this is even more difficult, as the
existing data is even less complete, and the additional
issues concerning the safety of the unborn child need to
be considered.
The goals of treating breast cancer in pregnancy are the
same as in any other setting, preserving the life and health
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local or regional disease, this means local and systemic
control of her disease. If the pregnancy is to be continued,
the treatment of the breast cancer may need to be modi-
fied minimize potential fetal toxicity. There is some con-
sensus that both surgery and chemotherapy can be
utilized during pregnancy, with some caveats [5]. The role
of radiation during pregnancy is more controversial [6],
but if required therapeutic radiation can often be delayed
until after delivery without disrupting the usual treatment
algorithm for the treatment of breast cancer. Hormone
therapy, if indicated, must wait until the completion of
the pregnancy.
A woman diagnosed with breast cancer in early pregnancy
has three basic options; terminate the pregnancy, delay all
treatment until after completion of pregnancy, continue
the pregnancy and proceed with a modified treatment
plan for her breast cancer based upon best available evi-
dence. While terminating the pregnancy is an option,
there is not data that this improves the probability of a
good cancer outcome [7].
Delaying treatment until after delivery is a reasonable
option for women diagnosed late in the third trimester.
However for women diagnosed earlier in pregnancy, a
prolonged delay in therapy potentially diminishes the
probability of cancer survival. Women diagnosed with
breast cancer during pregnancy tend to have high grade
cancer, with many having lymphovascular space invasion
[8]. The testing of hormone receptors during pregnancy is
controversial, but similar to age matched controls, many
pregnant women are reported to be receptor negative [9].
In addition, women diagnosed with breast cancer during
pregnancy tend to have more advanced disease compared
to non-pregnant women [10]. Biologic factors leading to
more rapid tumor growth may account for this observa-
tion [9,10]. These characteristics make the decision to
delay therapy worrisome, as the probability of upstaging
occurring during a delay may be higher than in non-preg-
nant patients.
Proceeding with a modified treatment plan during preg-
nancy represents the third and most frequently applied
option. Breast cancer surgery during pregnancy is consid-
ered relatively safe based upon available case series
[11,12]. Surgery is often delayed until after the first trimes-
ter due to the high rate of spontaneous abortion in the
first trimester. The experience with chemotherapy during
pregnancy is certainly limited. Based upon the available
literature, which is restricted to case reports, case series,
and one cohort study [13,14] the safety of chemotherapy
for mother and fetus is reasonable in the second and third
trimester. For instance, the rate of major congenital mal-
formations for chemotherapy during pregnancy has been
reported to be 3%, while that for the general population
is reported as 2–3% [15]. The regimens for which the most
information is available are the anthracycline containing
regimens, such as FAC and AC. While contemporary
chemotherapy might include a taxane, anthracycline con-
taining regimens are of proven efficacy, and based upon
the treatment schedule, a taxane could likely be given in
sequence after delivery.
Treatment recommendations are available based upon a
meeting of international experts as well as from the
National Comprehensive Cancer Network®; giving some
guidelines based upon the best available evidence [5,16].
It is incumbent upon us to continue to improve the lim-
ited knowledge we have regarding this complex issue.
Randomized trials will not be able to address this situa-
tion, and continued observation and reassessment of out-
comes of the women who encounter this situation
through national or international registry studies should
be encouraged.
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